Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement

Core Points - Burning Rock Biotech Limited has regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price of $1.00 per share for 10 consecutive business days [1][3] - The company was previously notified on December 29, 2023, that it was not in compliance due to its American depositary shares (ADSs) closing below the minimum bid price for 30 consecutive business days [2] - To regain compliance, the company adjusted the ratio of its ADSs from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares, effective May 15, 2024 [2] Company Overview - Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, offering NGS-based therapy selection testing for late-stage cancer patients and cancer early detection services [4] - The company's mission is to guard life via science, and it has progressed its early detection services beyond proof-of-concept R&D into the clinical validation stage [4]